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The ability to generate and respond to signaling molecules
establishes a mechanism for regulated cell-to-cell communica-
tion. Cells coordinate their growth and proliferation with
autocrine and paracrine signaling by means of low molecular
weight polypeptides called cytokines. Innate or natural immu-
nity is a highly conserved defense mechanism against infec-
tions found in all multicellular organisms [1]. The inflammatory
reaction is a fundamental component of the innate immune
response, and its most proximal expression is characterized by
the elaboration of proinflammatory cytokines — tumor necrosis
factor (TNF)-α and interleukin (IL)-1β. Response to cytokines
is generally viewed as exclusive to cells containing a defined
nucleus, since cytokines are intended to work on well-defined
eukaryotic cells with consequent signal transduction events.
When proinflammatory cytokines are present in optimal con-
centration, they recruit both specific and nonspecific
immune cells, nonlymphoid leukocytes (monocytes/
macrophages, neutrophils, basophils, and eosinophils), and
lymphocytes to the site of assault and activate them,
thereby helping to eradicate the assault and to restore
homeostasis [2]. There are occasions, however, when the
host defense response, in terms of inflammation, is exagger-
ated and protracted. In such cases, this primary defense
process may instead cause enhanced tissue injury and mal-
adaptive repair, leading to vital organ dysfunction and failure
[3]. Reduction in the effective concentration of proinflamma-
tory mediators is an important component in the resolution
of inflammation [4].
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Abstract
Clinical studies have shown positive associations among sustained and intense inflammatory
responses and the incidence of bacterial infections. We hypothesized that cytokines secreted by the
host during acute respiratory distress syndrome may indeed favor the growth of bacteria and explain
the association between exaggerated and protracted systemic inflammation and the frequent
development of nosocomial infections. To test this hypothesis, we conducted in vitro studies
evaluating the extracellular and intracellular growth response of three clinically relevant bacteria in
response to graded concentrations of pro-inflammatory cytokines tumor necrosis factor-α, IL-1β, and
IL-6. In these studies, we identified a U-shaped response of bacterial growth to pro-inflammatory
cytokines. When the bacteria were exposed in vitro to a lower concentration of cytokines, extracellular
and intracellular bacterial growth was not promoted and human monocytic cells were efficient in killing
the ingested bacteria. Conversely, when bacteria were exposed to higher concentrations of pro-
inflammatory cytokines, intracellular and extracellular bacterial growth was enhanced in a dose-
dependent manner. The bidirectional effects of proinflammatory cytokines on bacterial growth may help
to explain the frequent occurrence of nosocomial infections in patients with unresolving acute
respiratory distress syndrome.
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The concepts of microbial etiology and pathogenesis of
infectious diseases have undergone revisions since the
pioneer researcher of microbial diseases, Robert Koch, pos-
tulated the criteria for microbial etiology of diseases. During
the past decade, the emphasis in the study of the pathogen-
esis of infectious diseases has shifted from determining the
function of the cellular players in the inflammatory response
to the mediators that orchestrate this response [5]. The rela-
tionship between bacteria and inflammation is traditionally
viewed as unidirectional. Bacteria trigger inflammation,
which — as part of the host innate immune response —
destroys bacteria and localizes the spread of infection.
Although correct, this simple relationship does not provide a
complete picture of the pathogen–host interaction in acute
life-threatening infections. This unchallenged (precondi-
tioned) view of the pathogen–host interaction has influenced
for years the interpretation of objective clinical data in critical
care medicine. In this paper, the clinical literature on nosoco-
mial infections (NIs) in acute respiratory distress syndrome
(ARDS) will be reviewed. The results will then be presented
of a prospective study of ARDS patients that investigated
longitudinally the relationship between circulatory and pul-
monary proinflammatory cytokine levels, infections, and
outcome. The findings of this study, as well as those of other
groups, generated a novel hypothesis, suggesting that bac-
teria may grow in the presence of excessive cytokine levels.
The results of recent in vitro studies from our group in
support of this new hypothesis will also be reported.
Clinical observation in ARDS
ARDS is a frequent form of hypoxemic respiratory failure,
characterized by the acute development of diffuse lung
inflammation. In mortality data, after day three of ARDS,
most patients die following a prolonged period of ventilatory
support, during which they often develop fever and other
criteria for systemic inflammatory response syndrome [6],
clinical manifestations of infection [7–9], and multiple organ
dysfunction syndrome [10,11]. In the medical literature,
sepsis is associated with fatality in 36% to 90% of ARDS
nonsurvivors [7,8,10,11]. At necropsy, 69% of ARDS non-
survivors have histologic evidence of pneumonia [12].
These observations led to the hypothesis that, in ARDS, a
direct correlation may exist between development of NIs,
amplification of the systemic inflammatory response, and
higher mortality [13]. Faist and coworkers [14] proposed a
two-hit hypothesis in which NIs represent a second insult to
a previously injured and primed host, converting a low-
grade or regulated host response into an accelerated or
dysregulated host response (accelerated systemic inflam-
matory response syndrome), triggering new or progressive
organ dysfunction. Support for this hypothesis, however,
relied only on clinical studies that did not use strict criteria
for diagnosing NI. Furthermore, this broadly accepted
pathophysiological hypothesis (second hit hypothesis) was
never tested prospectively in ARDS.
Nosocomial infections and inflammation
Nosocomial infections and systemic inflammatory
response in ARDS
We conducted a prospective study to investigate, at the
onset of ARDS and during the progression of the disease,
the longitudinal relationship between circulatory proinflamma-
tory cytokine levels, infections, and outcome [15]. In most
patients, the etiology of ARDS was pulmonary or extrapul-
monary sepsis. We reported that, at the onset of ARDS, and
over time, nonsurvivors (n = 17) had significantly (P < 0.001)
higher plasma TNF-α, IL-1β, and IL-6 levels than survivors
(n = 17) did [16]. During the first week of ARDS, plasma
cytokine levels declined in all survivors, whereas they
remained persistently elevated in all nonsurvivors. NIs were
more frequent in patients with persistent cytokine elevation
over time. The rate of nosocomial infection per day of
mechanical ventilation was 1% in survivors and 8% in nonsur-
vivors. Moreover, none of the proven (n = 36) or suspected
(n = 55) NIs caused either a transient or a sustained increase
in plasma TNF-α, IL-1β, IL-6, and IL-8 levels above preinfec-
tion values [15]. This latter finding is in agreement with the
recent understanding of downregulation (also called
lipopolysaccharide [LPS] tolerance) of an activated system
(see discussion in reference [15]). In these patients, a plasma
IL-1β >400 pg/ml on day seven of ARDS was 100% accu-
rate in predicting outcome [15]. Sixty-seven percent of NI
developed after day 10 of ARDS, and among nonsurvivors,
15 out of 18 NIs developed while plasma IL-1β was
>400 pg/ml. In addition to our work [15], one other study
have described an association between high circulating IL-6
levels and increased rate of infections [17].
Ventilator-associated pneumonia and pulmonary
inflammation in ARDS
The relationship between ventilator-associated pneumonia
(VAP) and pulmonary inflammation was evaluated in a series
of prospective studies. We evaluated with bilateral bron-
choalveolar lavage (BAL) 94 ARDS patients with 172
episodes of suspected VAP and compared BAL results from
contralateral sites [18]. Thirty-three of the 55 (60%) positive
bronchoscopies had significant (>104 CFU/ml) growth in only
one side. Episodes with bilateral significant growth were
more likely to be polymicrobial, to have a bacterial growth
>105 CFU/ml in the BAL, and to possess a higher percent-
age of polymorphonuclear (PMN) cells and intracellular
microorganisms. These BAL findings indicated that episodes
with a higher bacterial burden had cytological evidence of a
more intense local inflammatory response and were more
likely to be diffuse. Postmortem studies have also described a
strong association between number of bacteria and severity
of local inflammation [19–21]. The traditional interpretation of
these data would suggest that the more severe inflammation
was the result of a higher bacterial burden; however, this rela-
tionship was challenged by the results of our prospective
study [22].Critical Care    February 2002 Vol 6 No 1 Meduri
In a longitudinal study of patients with ARDS, subjected to
bilateral BAL weekly and when clinical manifestations of VAP
developed, we reported that at the onset of ARDS and over
time, nonsurvivors had significantly (P < 0.001) higher BAL
TNF-α, IL-1β, and IL-6 levels than survivors did [22]. Nonsur-
vivors had a higher rate of VAP than survivors [15]. In 21
episodes of VAP (16 unilateral and five bilateral pneumonia)
there was excellent agreement between right and left BAL
TNF-α, IL-1β, IL-6, total protein, and albumin levels. In other
words, patients with unilateral pneumonia had similar TNF-α,
IL-1β, and IL-6 levels in the BAL obtained from the lung with
significant bacterial growth compared to the BAL from the
contralateral lung without growth [15]. Furthermore, VAPs
were not associated with either a transient or a sustained
increase in BAL TNF-α, IL-1β, IL-6, and IL-8 levels above pre-
infection values [15]. In agreement with our results, the find-
ings of a recent experimental study of gram-negative
pneumonia indicated that persistent elevation in BAL proin-
flammatory cytokines is associated with failure to clear intra-
pulmonary bacteria, despite a large influx of PMN in the
airspaces [23].
Experimental and human studies have shown that a lung
affected by ARDS is impaired in its ability to clear a bacterial
challenge. Several intrinsic defects have been previously
implicated, primarily those related to changes in the alveolar
environment and the function of phagocytic cells [2]. Poly-
morphonuclear cells recruited into the airspaces of patients
with ARDS have shown evidence of impaired microbicidal
activity [24,25]; this mechanism partly explains the lung’s
inability to clear bacteria in spite of intense local inflammation.
Furthermore, PMN clearing of bacteria is dose dependent,
and the efficiency of PMN bactericidal activity decreases with
increasing bacterial load [26].
Recent understanding of bacteria and
cytokine interaction
In the interaction between a microorganism and its host, the
host’s defense does not go unchallenged [27]. Several
reports have shown that DNA viruses have the ability to inter-
fere with extracellular cytokines or inhibit cytokine synthesis
[27]. Until recently, very little was known about the ability of
bacteria to interfere with, or to utilize, extracellular cytokines
secreted by the host cells or intracellular cytokines within
phagocytic cells. Recent reports have shown that certain
bacteria have receptors for cytokines IL-1β and TNF-α, and
that exposure of bacteria to these cytokines enhanced their
growth [28–30].
Receptors
The surfaces of bacteria have receptors for proinflammatory
cytokines. Gram-negative bacteria have receptors for TNF-α
and IL-1β [29–31], and the virulence property of the bac-
terium is altered as a consequence of cytokine binding [30].
Porat et al. [28] reported that virulent strains of Escherichia
coli express receptors for IL-1β and demonstrated enhanced
extracellular  in vitro growth in the presence of biologically
active recombinant IL-1β. Luo et al. [30] reported that TNF-α
could bind efficiently to many strains of gram-negative bacte-
ria and that TNF-α–bacterium complexes can interact with
TNF-α receptors present on eukaryotic cells. They also
showed that TNF-α binding enhanced bacterial invasion of
HeLa cells and phagocytosis by human and murine
macrophages [30]. We recently reported that the surfaces of
Staphylococcus aureus have receptors for IL-1β [32].
Enhanced bacterial growth with cytokines
Enhanced bacterial growth in the presence of cytokines has
been reported for E. coli (IL-1β [28], interferon-γ [33], IL-2
[34], and granulocyte macrophage colony stimulating factor
[34]) and S. aureus (IL-4) [35]. Two studies have reported
that the intracellular growth of Mycobacterium avium–intra-
cellular complex was enhanced in human peripheral blood
monocytes activated with the cytokines IL-3, IL-6, and granu-
locyte macrophage colony stimulating factor [36,37].
Anti-inflammatory cytokines have also been reported to
promote bacterial growth. Two studies have shown that IL-10
and IL-4 can enhance the intracellular replication of bacteria.
Park and Skerrett [38] reported that priming of human mono-
cytes with IL-10 significantly enhanced the intracellular
growth of Legionella pneumophila. Hultgren et al. [35]
reported reduced growth of S. aureus in the joints of an IL-4-
deficient mouse and showed that exposure of macrophages
to IL-4 reduced intracellular killing of S. aureus without
impairing phagocytosis. We recently reported that the extra-
cellular growth of S. aureus is enhanced in the presence of
IL-1 receptor antagonist [32].
New hypothesis and hypothesis testing
The findings from our studies described above [15,16,22] sug-
gested that final outcome in patients with ARDS is related to
the magnitude and duration of the host inflammatory response,
and that intercurrent NIs might be an epiphenomenon of pro-
longed intense inflammation. The increased rate of NIs might
be explained by impaired host defense response. We hypothe-
sized, however, that cytokines secreted by the host during
ARDS may indeed favor the growth of bacteria and explain the
association between an exaggerated and protracted release of
cytokines and the frequent development of NIs.
To test this hypothesis, we conducted in vitro studies evalu-
ating the extracellular and intracellular growth response of
three clinically relevant bacteria in response to graded con-
centrations of proinflammatory cytokines TNF-α, IL-1β, and
IL-6 [32,39–41]. The bacteria used were fresh isolates of
S. aureus,  Pseudomonas aeruginosa, and  Acinetobacter
sps obtained from patients with ARDS. The bacteria were
grown in 3 ml of RPMI/DMEM medium without serum or
antibiotics. Intracellular growth was tested in the human
monocytic cell line, U937, and in blood monocytes of
normal healthy volunteers.In these studies, we identified a U-shaped response of bacte-
rial growth to proinflammatory cytokines. When the bacteria
were exposed in vitro to a lower concentration (10–250 pg)
of TNF-α, IL-1β, or IL-6 — similar to the plasma values
detected in ARDS survivors [16] — extracellular and intracel-
lular bacterial growth was not promoted, and human mono-
cytic cells were efficient in killing the ingested bacteria
[39,40]. Conversely, when bacteria were exposed to higher
concentrations of these of proinflammatory cytokines —
similar to the plasma values detected in ARDS nonsurvivors
[16] — intracellular and extracellular bacterial growth were
enhanced in a dose-dependent manner [39,40]. Blockade by
specific neutralizing monoclonal antibodies significantly inhib-
ited cytokine-induced extracellular and intracelullar bacterial
growth [39,40].
The effects of cytokines on extracellular bacterial growth
were seen only with fresh isolates and were lost after six in
vitro passages [39]. These findings indicate that, in the host
milieu, S. aureus, Ps. aeruginosa, and Acinetobacter sps may
acquire a phenotypic ability to use cytokines as growth
factors; subsequent removal of these pathogens from such
milieu (after six in vitro passages) resulted in the loss of the
acquired phenotype. This phenomenon of loss of responsive-
ness to cytokines was also recorded by Porat and collabora-
tors [31].
Effects of LPS on intracellular bacterial growth
The intracellular growth of S. aureus,  Ps. aeruginosa, and
Acinetobacter sps was also tested after exposure of U937
monocytic cells to graded concentrations of LPS. At low
priming concentrations of LPS, we observed a significant
reduction in intracellular bacterial growth compared to the
control. At a priming concentration of LPS equal to, or greater
than, 100 ng, however, all three bacterial isolates had a signif-
icant growth enhancement compared to the control
(P < 0.0001, for all three bacteria). Taken together, our find-
ings indicate that there may be a threshold of cellular activa-
tion at which phagocytic cells effectively kill ingested
bacteria. Above this threshold of cellular activation, however,
the intracellular micromilieu becomes favorable to the survival
and replication of the ingested bacteria. It is likely that bacte-
ria that are internalized, and under selective pressure, may
adapt to an otherwise hostile microenvironment by switching
on novel gene expression that enables them to utilize
cytokines as their growth factors.
Effects of methylprednisolone on intracellular
bacterial growth
We exposed U937 monocytic cells primed with the highest
concentration of LPS (10 µg) to escalating concentrations
(0 µg, 25 µg, 50 µg, 75 µg, 100 µg, 150 µg, and 250 µg) of
methylprednisolone and quantified both intracellular bacterial
growth and the intracellular transcription of TNF-α, IL-1β,
and IL-6. We found that exposure of LPS-primed U937
monocytic cells to methylprednisolone prior to infection
affected (in a dose-dependent manner) the mRNA expres-
sion of TNF-α, IL-1β, and IL-6, and the in vitro intracellular
bacterial growth of internalized S. aureus, Ps. aeruginosa,
and Acinetobacter sps [41].
The impairment in intracellular bacterial killing correlated with
the increased expression of proinflammatory cytokines, while
restoration of monocyte killing function upon exposure to
methylprednisolone coincided with the downregulation of the
expression of TNF-α, IL-1β, and IL-6. We found that, at the
two highest concentrations of methylprednisolone (150 µg
and 250 µg), the mRNA expression of all three cytokines was
significantly blunted, irrespective of the LPS concentration.
Hence, we presume that bacterial survival and replication
within the phagocytic cells are functions of the cytokines
expressed by such cells. In the presence of excessive activa-
tion, the intracellular environment appears to favor the emer-
gence of new phenotypes of bacteria that are capable of
utilizing cytokines for their growth. By showing that methyl-
prednisolone can reduce (in a dose-dependent manner) the
mRNA expression of TNF-α, IL-1β, and IL-6, and the intracel-
lular bacterial growth of the bacteria, we provide experimental
evidence to suggest a cause-and-effect relationship between
excessive inflammation and bacterial growth.
Bacteria and cytokine interactions
It is unclear how bacteria may use cytokines for their growth,
since bacteria are prokaryotes without a defined nucleus and
cytokines are intended to work on well-defined eukaryotic
cells with consequent signal transduction events. In a host
milieu, however, bacteria may adapt to eukaryotic cellular
processes [42]. Although, the subsequent sequence of intra-
cellular events has not been delineated, it is possible that
bacteria might use cytokines through receptor-mediated,
signal-transduction-induced activities that would require the
presence of biochemical processes akin to those seen in
eukaryotic cells. Cytokines may act on bacteria through a sig-
naling process similar to that of eukaryotes, but involving dif-
ferent biochemical pathways, or bacteria may break down
cytokines into biologically active fragments that are trans-
ported across the bacterial cell membranes and act on spe-
cific gene transcription and translation.
To further elucidate the complex interactions between bacte-
ria and cytokines, we conducted in vitro experiments using
S. aureus to demonstrate the presence of IL-1 receptors on
the surface of S. aureus, and to localize the region(s) of IL-1β
that enhance the extracellular growth of S. aureus. We identi-
fied an IL-1β receptor on the surface of the bacterium and we
utilized five linear peptide fragments of human IL-1β and
whole biologically active molecules of both IL-1 receptor
antagonist and IL-1β to study their effects on extracellular
growth of S. aureus. Of the five peptide fragments studied,
the 208–240 peptide fragment demonstrated the most pro-
nounced effect on the growth of S. aureus. Previously, this
fragment has been shown to be pyrogenic and to enhance
Available online http://ccforum.com/content/6/1/024sleep in rabbits [43]. This peptide fragment, however, does
not have mitogenic activity on T cells in vitro, indicating its
probable lack of ability to interact specifically with IL-1 recep-
tor (although the possibility of a receptor–ligand interaction
cannot be completely ruled out). This peptide (208–240)
enhanced the growth of S. aureus approximately 22-fold
compared to the control (bovine serum albumin). Another
peptide spanning amino acids 118–147 also enhanced the
extracellular growth of S. aureus significantly, although much
less efficiently, than the peptide fragment 208–240. No sig-
nificant effects were exerted on S. aureus growth by the
other 3 fragments studied. No biological activities in any other
systems have been reported for any of the peptides studied
other than for the one spanning 208–240.
Several proteinases are released from S. aureus into the
extracellular medium [44] and it is therefore possible that
such enzymes may cleave the IL-1β molecule into peptide
fragments. Such short peptide fragments may then be trans-
ported across the bacterial cell membrane and act as direct
growth factors, or as transcription factors, for the production
of bacterial growth factors. This remains speculative at this
time since there is no direct proof of such cleavage activities
of  S. aureus extracellular proteinases on IL-1β. There are,
however, reports of proteolytic cleavages of IL-2, TNF-α,
and/or interferon-γ by bacterial products of Ps. aeruginosa
and Legionella pneumophila [5].
Conclusion
The bidirectional effects of proinflammatory cytokines on bac-
terial growth may help explain the frequent occurrence of NIs
in patients with unresolving ARDS. Table 1 shows the tradi-
tional versus alternative interpretations of clinical findings in
ARDS. If NIs in unresolving ARDS are indeed an epiphenom-
enon of exaggerated inflammation, it follows that treatment
modalities that effectively decrease cytokine synthesis may
reduce the incidence or severity of NIs.
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